Komori
Earnings presentation materials2395SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.Information and Communications, Services and Others

New Medium-Term Management Plan: Transformation 2030 (Earnings Briefing Materials)

The company presented a plan to achieve net sales of at least ¥70 billion, ordinary profit of at least ¥20 billion, and ROE and ROIC of at least 10% each in FY2030 as its new medium-term management plan, replacing 2028 Vision. In addition to the global expansion of its CRO business, the company plans to make its TR business a core earnings driver through the commercialisation of Atzumi.

Worth reading
50Recurring
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
700
¥100 million (FY2030 net sales target: ¥70 billion or more)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Medium-Term Management Plan PresentationFY20306 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥700 100 million or more
Ordinary income¥200 100 million or more excluding foreign exchange effects
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate¥150 per US$1 (Satsuma plan conversion rate)
New initiatives
  • Formulation of the new medium-term management plan, Transformation 2030
  • Global expansion of the CRO business by increasing its overseas share
  • Building a sales structure for the launch of Atzumi sales in the second half of 2027
  • Promotion of DX and AX
  • Partnering and technology out-licensing in the TR business, and research on an intranasal influenza vaccine
Medium-term management plan targets
Net Sales¥70 billion or more (FY2030)
Ordinary income¥20 billion or more (FY2030)
Ordinary profit margin28.5% or more (FY2030)
ROE10% or more (FY2030)
ROIC10% or more (FY2030)
Ordinary profit (excluding foreign exchange effects) + strategic investment amount¥30 billion or more, with a profit margin of 40% or more (FY2030)
Financial targets
ROE10% or more (FY2030)
ROIC10% or more (FY2030)
Market Size / Share
U.S. acute migraine marketUSD 2.8B（2025）
Patients with an inadequate response to existing treatmentsApproximately 30% (based on prescription volume)
Orders received and order backlog
Order intake in the non-clinical businessGraph showing the FY2030 plan; specific figures Not disclosed
Contents of this document
ItemDetails
Document typeMedium-Term Management Plan Presentation
Fiscal Period CoveredFY2030
Net Sales¥700 100 million or more
Ordinary income¥200 100 million or more (excluding foreign exchange effects)
Assumptions Underlying the Business OutlookExchange rate ¥150 per US$1 (Satsuma plan conversion rate)
Medium-term management plan targetsNet Sales ¥70 billion or more (FY2030) / Ordinary income ¥20 billion or more (FY2030) / Ordinary profit margin 28.5% or more (FY2030) / ROE 10% or more (FY2030) / ROIC 10% or more (FY2030) / Ordinary profit (excluding foreign exchange effects) + strategic investment amount ¥30 billion or more, with a profit margin of 40% or more (FY2030)
Financial targetsROE 10% or more (FY2030) / ROIC 10% or more (FY2030)
Orders received and order backlogOrder intake in the non-clinical business Graph showing the FY2030 plan; specific figures Not disclosed
Market Size / ShareU.S. acute migraine market USD 2.8B（2025） / Patients with an inadequate response to existing treatments Approximately 30% (based on prescription volume)
New initiativesFormulation of the new medium-term management plan, Transformation 2030, Global expansion of the CRO business by increasing its overseas share, Building a sales structure for the launch of Atzumi sales in the second half of 2027, Promotion of DX and AX, Partnering and technology out-licensing in the TR business, and research on an intranasal influenza vaccine
Items this document does not state (21)
Operating profitNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To further expand the CRO business globally and monetise the TR business through the commercialisation of Atzumi (Satsuma).

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
New Medium-Term Management Plan: Transformation 2030 (Earnings Briefing Materials) | SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395) timely disclosure | Komori